Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Dihydrotestosterone (DHT) mainly affects nearby cells, doesn't significantly change prostate hormonal environment or cancer risk, and doesn't play a main role in causing hair loss or acne. More research is needed on its effects on heart health, sexual function, and bone health.

Hormonal balance is vital for women's health and performance, but therapies like contraceptives and steroids have both benefits and risks.

Testosterone therapy and surgeries like mastectomy improve transgender men's lives and mental health with low risks and high satisfaction.

Hormonal contraceptives and related compounds can increase health risks like thrombosis and affect sexual function.

Antiandrogenic drugs could be a good treatment option for frontal fibrosing alopecia.

Testosterone therapy is generally safe for transmen, improves sexual function, and has manageable health risks with proper monitoring.

Exposure to certain sex hormones can increase health risks, while some hormone therapies may offer benefits for specific conditions.

Environmental factors, hormones, nutrition, and stress all significantly affect skin health and aging.

The document concludes that low-dose oral contraceptives and hormonal therapies can manage perimenopause symptoms and reduce some health risks, but lifestyle changes and disease screening are also important.

PCOS negatively affects women's quality of life, especially if not detected early.

Healthy aging can be promoted through physical activity, lifestyle changes, and certain treatments.

Advancements in male reproductive medicine are ongoing, but more research and improved treatments are needed in several areas.

LGBT individuals have unique skin health needs, including higher STD risks and side effects from gender-affirming treatments, requiring dermatologists to offer knowledgeable and culturally competent care.

The guideline emphasizes a multidisciplinary approach and informed consent for gender-affirming hormone treatment, with regular follow-ups and individualized care.

Australia needs better dermatological guidelines for gender-diverse patients.

The document concludes that accurate diagnosis of male and female gonadal disorders is crucial for effective treatment and better patient outcomes.

Doctors recommend postoperative radiation for male breast cancer, advise against testosterone for vasomotor symptoms post-adrenalectomy, suggest non-hormonal treatments for atrophic vaginitis after mastectomy, note no specific treatment for anticoagulant-induced hair loss, and call for more research on silicosis from silicon carbide exposure.

Melanoma patients can learn to check their skin, early balding in men may indicate similar risks as PCOS in women, certain criteria can help predict skin cancer behavior, small skin cancer may not need extra therapy after surgery, and sterile gloves don't reduce infection in minor surgeries.

Finasteride is effective for treating BPH but not recommended for prostate cancer prevention.

Removing both ovaries may better treat increased male hormone levels and related symptoms in postmenopausal women when hormone therapy doesn't work.

The document concludes that skin aging in women can be caused by UV exposure and hormonal changes, and treatments like hormone replacement therapy and various skin therapies can help.

Anti-cancer drugs are diverse and hard to classify due to their different forms and actions.

Chemotherapy can harm kidneys in breast cancer patients.

Local estrogen synthesis in skin may improve wound healing.

New steroid compounds may help with hormonal therapy and have potential benefits for glucose disorders, but more research is needed.

Immunotherapy for cancer caused a patient to develop a condition affecting hormone production, requiring ongoing hormone replacement therapy.

Personalized supplements are important for women's health, but hormone therapy can increase cancer and heart risks.

Some hormone treatments might raise breast cancer risk, while others don't seem to.

5α-reductase inhibitors lower overall prostate cancer risk but not high-grade cancer risk; longer-term screening and new treatments show promise.

Chemotherapy often causes skin and hair issues, but early management can help improve patient care.